These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 12410375)

  • 1. Successful pregnancy in a patient having high basal serum levels of sex steroid hormones.
    Furuhashi M; Suganuma N; Nishimori K
    Arch Gynecol Obstet; 2002 Nov; 267(1):46-8. PubMed ID: 12410375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interventions after artificial insemination: conception rates, pregnancy survival, and ovarian responses to gonadotropin-releasing hormone, human chorionic gonadotropin, and progesterone.
    Stevenson JS; Portaluppi MA; Tenhouse DE; Lloyd A; Eborn DR; Kacuba S; DeJarnette JM
    J Dairy Sci; 2007 Jan; 90(1):331-40. PubMed ID: 17183101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
    de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerated endometrial maturation in the luteal phase of cycles utilizing controlled ovarian hyperstimulation: impact of gonadotropin-releasing hormone agonists versus antagonists.
    Saadat P; Boostanfar R; Slater CC; Tourgeman DE; Stanczyk FZ; Paulson RJ
    Fertil Steril; 2004 Jul; 82(1):167-71. PubMed ID: 15237007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time and incidence of ovulation and conception rates after incorporating estradiol cypionate into a timed artificial insemination protocol.
    Sellars CB; Dalton JC; Manzo R; Day J; Ahmadzadeh A
    J Dairy Sci; 2006 Feb; 89(2):620-6. PubMed ID: 16428631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
    Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
    Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased progesterone/estradiol ratio on the day of HCG administration adversely affects success of in vitro fertilization-embryo transfer in patients stimulated with gonadotropin-releasing hormone agonist and recombinant follicle-stimulating hormone.
    Ou YC; Lan KC; Chang SY; Kung FT; Huang FJ
    Taiwan J Obstet Gynecol; 2008 Jun; 47(2):168-74. PubMed ID: 18603501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
    Krause BT; Ohlinger R
    Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaginal progesterone administration before ovulation induction with exogenous gonadotropins in polycystic ovarian syndrome.
    Buckler HM; Phillips SE; Cameron IT; Healy DL; Burger HG
    J Clin Endocrinol Metab; 1988 Aug; 67(2):300-6. PubMed ID: 3134388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship of changes in serum estradiol and progesterone during the menstrual cycle to the thyrotropin and prolactin responses to thyrotropin-releasing hormone.
    Sawin CT; Hershman JM; Boyd AE; Longcope C; Bacharach P
    J Clin Endocrinol Metab; 1978 Dec; 47(6):1296-302. PubMed ID: 122427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The abnormal response of polycystic ovarian disease patients to exogenous pulsatile gonadotropin-releasing hormone: characterization and management.
    Filicori M; Flamigni C; Campaniello E; Valdiserri A; Ferrari P; Meriggiola MC; Michelacci L; Pareschi A
    J Clin Endocrinol Metab; 1989 Oct; 69(4):825-31. PubMed ID: 2506216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine modifications associated with final oocyte maturation with gonadotropin-releasing hormone agonists vs. human chorionic gonadotropin in women undergoing intrauterine insemination.
    Díaz I; Guillén A; Pacheco A; Requena A; Garcia-Velasco JA
    J Reprod Med; 2008 Jan; 53(1):33-9. PubMed ID: 18251359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian stimulation during gonadotropin treatment after hCG administration monitored by ultrasound and serum estradiol and progesterone.
    Ylöstalo P; Siegberg R
    Int J Fertil; 1988; 33(4):259-64. PubMed ID: 2902041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels.
    Manzanares MA; Gómez-Palomares JL; Ricciarelli E; Hernández ER
    Fertil Steril; 2010 Mar; 93(4):1215-9. PubMed ID: 19200978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of gonadotropin-releasing hormone pulse frequency is associated with subsequent selective follicle-stimulating hormone secretion in women with polycystic ovarian disease.
    Christman GM; Randolph JF; Kelch RP; Marshall JC
    J Clin Endocrinol Metab; 1991 Jun; 72(6):1278-85. PubMed ID: 1902845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent megalocystic ovary following in vitro fertilization in a postpartum patient with polycystic ovarian syndrome.
    Ling SY; Chong KM; Hwang JL
    Taiwan J Obstet Gynecol; 2006 Mar; 45(1):70-2. PubMed ID: 17272214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum inhibin levels in polycystic ovary syndrome: basal levels and response to luteinizing hormone-releasing hormone agonist and exogenous gonadotropin administration.
    Buckler HM; McLachlan RI; MacLachlan VB; Healy DL; Burger HG
    J Clin Endocrinol Metab; 1988 Apr; 66(4):798-803. PubMed ID: 3126215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of electroacupuncture intervention on changes of quality of ovum and pregnancy out- come in patients with polycystic ovarian syndrome].
    Yang BZ; Cui W; Li J
    Zhen Ci Yan Jiu; 2015 Apr; 40(2):151-6. PubMed ID: 26054202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.